Regeneron initiates study on linvoseltamab for high-risk monoclonal gammopathy
Regeneron Pharmaceuticals is conducting a proof-of-concept study to evaluate linvoseltamab's efficacy in eliminating abnormal plasma cells in patients at risk of multiple myeloma.